August 29, 2022 The Honorable Charles Schumer Majority Leader, U.S. Senate Washington, DC 20510 The Honorable Nancy Pelosi Speaker, U.S. House of Representatives Washington, DC 20515 The Honorable Mitch McConnell Minority Leader, U.S. Senate Washington, DC 20510 The Honorable Kevin McCarthy Minority Leader, U.S. House of Representatives Washington, DC 20515 The Honorable Patty Murray Chair, U.S. Senate HELP Committee Washington, DC 20510 The Honorable Frank Pallone Chair, Committee on Energy & Commerce U.S. House of Representatives Washington, DC 20515 The Honorable Richard Burr Ranking Member, U.S. Senate HELP Committee Washington, DC 20510 The Honorable Cathy McMorris Rogers Ranking Member, Committee on Energy & Commerce, U.S. House of Representatives Washington, DC 20515 Dear Speaker Pelosi, Leaders Schumer, McCarthy and McConnell, Chairs Pallone and Murray, and Ranking Members Rogers and Burr: We write as a diverse group of consumer, health professional, food safety, academic, and environmental organizations that wish to express appreciation of your continuing efforts to deliver vital funding to the Food and Drug Administration (FDA) through user fee reauthorization legislation emerging from the House Energy and Commerce Committee and the Senate Health, Education, Labor and Pensions (HELP) Committee. We urge that as you work to reconcile these bills, you address urgent public health challenges by maintaining critical protections in the FDA Safety and Landmark Advancements Act (FDASLA), S. 4348. This legislation includes safeguards that will help ensure Americans have access to safe dietary supplements, accurate tests used in clinical medicine, a safe and reliable supply of infant formula and other essential medical foods, food packaging free of harmful PFAS chemicals, safe cosmetics, and affordable and timely access to effective and safe medicines tested in diverse populations. These necessary, bipartisan policies reflect years of continuous engagement and thoughtful collaboration among committee and congressional leaders, the executive branch, and the public stakeholder community. Our organizations deeply appreciate the careful balance the Senate HELP Committee struck in the legislation it advanced to markup on June 14th, 2022. While some provisions could be strengthened still further from the Senate version, we urge you not to forgo this key opportunity to advance long-awaited solutions for the American public. We express our continued support for the meaningful reforms contained in the bill, and hope that Congressional and committee leadership remain committed to negotiating these protections as you advance this important legislation. For questions and further assistance on this letter, please contact Sarah Sorscher at ssorscher@cspinet.org or (202) 777-8397. Signed, Allergy & Asthma Network AllergyStrong American Partnership for Eosinophilic Disorders (APFED) Association of State Public Health Nutritionists Asthma and Allergy Foundation of America BISA Nonprofit - Breast Implant Safety Alliance Center for Environmental Health Center for Food Safety Center for Foodborne Illness Research & Prevention Center for Science in the Public Interest Consumer Federation of America Consumer Reports CURED Campaign Urging Research for Eosinophilic Diseases Doctors for America Elijah-Alavi Foundation Environmental Working Group Eosinophilic Family Coalition FARE (Food Allergy Research and Education) Food Equality Initiative International Center for Technology Assessment International FPIES Association Jacobs Institute of Women's Health National Center for Health Research Patients For Affordable Drugs Now T1International USA The TMJ Association U.S. PIRG (Public Interest Research Group)